Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.80
NAS:MYGN's Cash-to-Debt is ranked lower than
69% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. NAS:MYGN: 0.80 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:MYGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.75  Med: No Debt Max: No Debt
Current: 0.8
Equity-to-Asset 0.57
NAS:MYGN's Equity-to-Asset is ranked lower than
53% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:MYGN: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:MYGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.9 Max: 0.96
Current: 0.57
0.57
0.96
Interest Coverage 37.54
NAS:MYGN's Interest Coverage is ranked lower than
54% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 55.24 vs. NAS:MYGN: 37.54 )
Ranked among companies with meaningful Interest Coverage only.
NAS:MYGN' s Interest Coverage Range Over the Past 10 Years
Min: 37.54  Med: No Debt Max: No Debt
Current: 37.54
Piotroski F-Score: 4
Altman Z-Score: 2.45
Beneish M-Score: -2.90
WACC vs ROIC
4.36%
10.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 13.00
NAS:MYGN's Operating Margin % is ranked higher than
75% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. NAS:MYGN: 13.00 )
Ranked among companies with meaningful Operating Margin % only.
NAS:MYGN' s Operating Margin % Range Over the Past 10 Years
Min: -30.37  Med: 35.81 Max: 39.24
Current: 13
-30.37
39.24
Net Margin % 9.72
NAS:MYGN's Net Margin % is ranked higher than
80% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. NAS:MYGN: 9.72 )
Ranked among companies with meaningful Net Margin % only.
NAS:MYGN' s Net Margin % Range Over the Past 10 Years
Min: -22.25  Med: 22.63 Max: 42
Current: 9.72
-22.25
42
ROE % 9.71
NAS:MYGN's ROE % is ranked higher than
65% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. NAS:MYGN: 9.71 )
Ranked among companies with meaningful ROE % only.
NAS:MYGN' s ROE % Range Over the Past 10 Years
Min: -11.85  Med: 18.28 Max: 30.71
Current: 9.71
-11.85
30.71
ROA % 7.06
NAS:MYGN's ROA % is ranked higher than
77% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. NAS:MYGN: 7.06 )
Ranked among companies with meaningful ROA % only.
NAS:MYGN' s ROA % Range Over the Past 10 Years
Min: -10.72  Med: 16.98 Max: 28.73
Current: 7.06
-10.72
28.73
ROC (Joel Greenblatt) % 66.09
NAS:MYGN's ROC (Joel Greenblatt) % is ranked higher than
85% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. NAS:MYGN: 66.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:MYGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -199.02  Med: 251.31 Max: 362.64
Current: 66.09
-199.02
362.64
3-Year Revenue Growth Rate 11.70
NAS:MYGN's 3-Year Revenue Growth Rate is ranked higher than
74% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. NAS:MYGN: 11.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:MYGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.6  Med: 20.1 Max: 31.4
Current: 11.7
1.6
31.4
3-Year EBITDA Growth Rate -2.50
NAS:MYGN's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. NAS:MYGN: -2.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:MYGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.2  Med: 12.15 Max: 48.5
Current: -2.5
-10.2
48.5
3-Year EPS without NRI Growth Rate -1.10
NAS:MYGN's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. NAS:MYGN: -1.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:MYGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -17.1  Med: 3.3 Max: 68.8
Current: -1.1
-17.1
68.8
GuruFocus has detected 6 Warning Signs with Myriad Genetics Inc $NAS:MYGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:MYGN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MYGN Guru Trades in Q1 2016

RS Investment Management 2,178,740 sh (+9.00%)
Jim Simons 1,034,800 sh (+8.97%)
Paul Tudor Jones 22,391 sh (+4.70%)
Joel Greenblatt 201,527 sh (+2.63%)
Ken Fisher 89,783 sh (+0.01%)
Mario Gabelli 25,000 sh (unchged)
Chuck Royce 1,284,698 sh (-9.20%)
» More
Q2 2016

MYGN Guru Trades in Q2 2016

First Eagle Investment 368,980 sh (New)
Lee Ainslie 93,870 sh (New)
Joel Greenblatt 360,830 sh (+79.05%)
Jim Simons 1,332,300 sh (+28.75%)
Ken Fisher 92,236 sh (+2.73%)
Mario Gabelli 25,000 sh (unchged)
RS Investment Management Sold Out
Chuck Royce 937,498 sh (-27.03%)
Paul Tudor Jones 14,167 sh (-36.73%)
» More
Q3 2016

MYGN Guru Trades in Q3 2016

Ron Baron 40,000 sh (New)
Paul Tudor Jones 31,742 sh (+124.06%)
Jim Simons 2,931,674 sh (+120.05%)
Lee Ainslie 152,050 sh (+61.98%)
Joel Greenblatt 421,728 sh (+16.88%)
Ken Fisher 92,381 sh (+0.16%)
First Eagle Investment Sold Out
Mario Gabelli Sold Out
Chuck Royce 90,369 sh (-90.36%)
» More
Q4 2016

MYGN Guru Trades in Q4 2016

Ron Baron 80,000 sh (+100.00%)
Paul Tudor Jones 47,033 sh (+48.17%)
Lee Ainslie 190,720 sh (+25.43%)
Chuck Royce Sold Out
Jim Simons 2,686,174 sh (-8.37%)
Joel Greenblatt 289,042 sh (-31.46%)
Ken Fisher 59,731 sh (-35.34%)
» More
» Details

Insider Trades

Latest Guru Trades with MYGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:BASI, NYSE:BIO » details
Traded in other countries:MYD.Germany,
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Myriad Genetics develops genetic diagnostic products. It is best known for its BRACAnalysis test, which assesses a woman's risk of developing hereditary breast and ovarian cancer. The company is transitioning its hereditary cancer tests to a single multigene panel, myRisk, which screens 25 genes across multiple cancer indications. Other products include Prolaris (prostate cancer) and other prognostic tests. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

Ratios

vs
industry
vs
history
PE Ratio 19.07
MYGN's PE Ratio is ranked higher than
71% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. MYGN: 19.07 )
Ranked among companies with meaningful PE Ratio only.
MYGN' s PE Ratio Range Over the Past 10 Years
Min: 9.06  Med: 19.05 Max: 63.15
Current: 19.07
9.06
63.15
Forward PE Ratio 17.51
MYGN's Forward PE Ratio is ranked higher than
65% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 17.51 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.07
MYGN's PE Ratio without NRI is ranked higher than
72% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.43 vs. MYGN: 19.07 )
Ranked among companies with meaningful PE Ratio without NRI only.
MYGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.06  Med: 18.41 Max: 40.65
Current: 19.07
9.06
40.65
Price-to-Owner-Earnings 27.08
MYGN's Price-to-Owner-Earnings is ranked higher than
50% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.53 vs. MYGN: 27.08 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MYGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.71  Med: 22.61 Max: 113.28
Current: 27.08
9.71
113.28
PB Ratio 1.77
MYGN's PB Ratio is ranked higher than
84% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. MYGN: 1.77 )
Ranked among companies with meaningful PB Ratio only.
MYGN' s PB Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.67 Max: 8.23
Current: 1.77
1.46
8.23
PS Ratio 1.80
MYGN's PS Ratio is ranked higher than
73% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. MYGN: 1.80 )
Ranked among companies with meaningful PS Ratio only.
MYGN' s PS Ratio Range Over the Past 10 Years
Min: 1.48  Med: 4.54 Max: 14.31
Current: 1.8
1.48
14.31
Price-to-Free-Cash-Flow 13.00
MYGN's Price-to-Free-Cash-Flow is ranked higher than
77% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.41 vs. MYGN: 13.00 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MYGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.62  Med: 16.64 Max: 44.11
Current: 13
7.62
44.11
Price-to-Operating-Cash-Flow 12.17
MYGN's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.08 vs. MYGN: 12.17 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MYGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.22  Med: 15.61 Max: 43.64
Current: 12.17
7.22
43.64
EV-to-EBIT 13.54
MYGN's EV-to-EBIT is ranked higher than
73% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.11 vs. MYGN: 13.54 )
Ranked among companies with meaningful EV-to-EBIT only.
MYGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -102.5  Med: 10.2 Max: 44
Current: 13.54
-102.5
44
EV-to-EBITDA 9.99
MYGN's EV-to-EBITDA is ranked higher than
74% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. MYGN: 9.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -161.3  Med: 9.5 Max: 38.5
Current: 9.99
-161.3
38.5
PEG Ratio 3.13
MYGN's PEG Ratio is ranked lower than
54% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. MYGN: 3.13 )
Ranked among companies with meaningful PEG Ratio only.
MYGN' s PEG Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.11 Max: 5.49
Current: 3.13
0.47
5.49
Shiller PE Ratio 14.82
MYGN's Shiller PE Ratio is ranked higher than
90% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.08 vs. MYGN: 14.82 )
Ranked among companies with meaningful Shiller PE Ratio only.
MYGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 12.23  Med: 46.6 Max: 2553
Current: 14.82
12.23
2553
Current Ratio 4.13
MYGN's Current Ratio is ranked higher than
71% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. MYGN: 4.13 )
Ranked among companies with meaningful Current Ratio only.
MYGN' s Current Ratio Range Over the Past 10 Years
Min: 1.17  Med: 5.96 Max: 20.28
Current: 4.13
1.17
20.28
Quick Ratio 3.51
MYGN's Quick Ratio is ranked higher than
71% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. MYGN: 3.51 )
Ranked among companies with meaningful Quick Ratio only.
MYGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.98  Med: 5.96 Max: 20.28
Current: 3.51
0.98
20.28
Days Inventory 87.77
MYGN's Days Inventory is ranked lower than
54% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.07 vs. MYGN: 87.77 )
Ranked among companies with meaningful Days Inventory only.
MYGN' s Days Inventory Range Over the Past 10 Years
Min: 22.14  Med: 48.49 Max: 87.77
Current: 87.77
22.14
87.77
Days Sales Outstanding 52.30
MYGN's Days Sales Outstanding is ranked higher than
61% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. MYGN: 52.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.41  Med: 46.88 Max: 72.25
Current: 52.3
38.41
72.25
Days Payable 50.78
MYGN's Days Payable is ranked lower than
55% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. MYGN: 50.78 )
Ranked among companies with meaningful Days Payable only.
MYGN' s Days Payable Range Over the Past 10 Years
Min: 48.96  Med: 80.13 Max: 280.85
Current: 50.78
48.96
280.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 5.00
MYGN's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 133 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. MYGN: 5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: -6.5 Max: 5.9
Current: 5
-13.6
5.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.53
MYGN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
94% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. MYGN: 0.53 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MYGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.47  Med: 1.13 Max: 20.87
Current: 0.53
0.47
20.87
Price-to-Median-PS-Value 0.40
MYGN's Price-to-Median-PS-Value is ranked higher than
87% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. MYGN: 0.40 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 1.42 Max: 9.95
Current: 0.4
0.35
9.95
Earnings Yield (Greenblatt) % 7.37
MYGN's Earnings Yield (Greenblatt) % is ranked higher than
85% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. MYGN: 7.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.3  Med: 8.8 Max: 22.7
Current: 7.37
2.3
22.7
Forward Rate of Return (Yacktman) % 8.66
MYGN's Forward Rate of Return (Yacktman) % is ranked higher than
52% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. MYGN: 8.66 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MYGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -19.9  Med: 3.8 Max: 29.6
Current: 8.66
-19.9
29.6

More Statistics

Revenue (TTM) (Mil) $750.9
EPS (TTM) $ 1.00
Beta0.26
Short Percentage of Float53.58%
52-Week Range $15.15 - 39.74
Shares Outstanding (Mil)68.09

Analyst Estimate

Jun17 Jun18 Jun19 Jun20
Revenue (Mil $) 749 753 765 854
EPS ($) 1.07 1.03 0.95 1.17
EPS without NRI ($) 1.07 1.03 0.95 1.17
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-1.19%
Dividends per Share ($)
» More Articles for NAS:MYGN

Headlines

Articles On GuruFocus.com
Casualty List Has Done Well; Here’s the Latest Jan 18 2017 
Industrial Companies Showing Good Potential for 2017 Jan 04 2017 
Gurus and Insiders Invest in Industrial and Medical Companies Dec 30 2016 
Chuck Royce Reduces Several Positions in 4th Quarter Feb 05 2016 
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 

More From Other Websites
Myriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical... Mar 20 2017
Myriad Genetics (MYGN) Launches EndoPredict Test in the US Mar 14 2017
Myriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast Cancer Mar 13 2017
Why Is Myriad Genetics (MYGN) Up 15.8% Since the Last Earnings Report? Mar 10 2017
Bullish and Bearish Reversals in the Market Feb 27 2017
Post Earnings Coverage as Myriad's Q2 Top-line Grew 2%; Topped Estimates Feb 27 2017
GeneSight® Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study... Feb 23 2017
Myriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with... Feb 17 2017
Myriad’s Prolaris® Test Significantly Improves the Risk Classification for One Third of Men... Feb 17 2017
Myriad Genetics, Inc. breached its 50 day moving average in a Bullish Manner : MYGN-US : February... Feb 14 2017
MYRIAD GENETICS INC Financials Feb 11 2017
Myriad Genetics to Join S&P SmallCap 600 Feb 10 2017
Myriad Genetics, Inc. :MYGN-US: Earnings Analysis: Q2, 2017 By the Numbers : February 9, 2017 Feb 09 2017
Myriad Genetics (MYGN): Q2 Impressive, 2017 View a Drag Feb 09 2017
MYRIAD GENETICS INC Files SEC form 10-Q, Quarterly Report Feb 08 2017
Wednesday’s Biggest Biopharma Movers Feb 08 2017
Myriad Genetics: Fairly Valued? Feb 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)